Drug: rovalpituzumab tesirine
Other Name: SC16LD6.5
- The participant must not be eligible for a Rovalpituzumab Tesirine clinical trial.
- Pediatric participants may be evaluated on a case by case basis.
AbbVie CALL CENTER
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.